Eupraxia Pharmaceuticals (EPRX) Operating Expenses (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Operating Expenses of $16.0 million for Q1 2026, up 123.98% year-over-year from $7.1 million in Q1 2025, and down 1.27% quarter-over-quarter from $16.2 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Operating Expenses (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Operating Expenses for 4 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 123.98% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $47.3 million (up 72.29% YoY), while the FY2025 annual figure was $38.4 million, up 42.33% from the prior year.
- Operating Expenses fell to $16.0 million in Q1 2026 per EPRX's latest filing, from $16.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $16.2 million in Q4 2025 and bottomed at $3.5 million in Q1 2023.
- Historically, Operating Expenses has averaged $8.4 million across 4 years, with a median of $6.9 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Expenses slumped 37.54% — and 2026, when it soared 123.98%.
- Eupraxia Pharmaceuticals' Operating Expenses stood at $12.0 million in 2023, then sank by 37.54% to $7.5 million in 2024, then jumped by 116.03% to $16.2 million in 2025, then dropped by 1.27% to $16.0 million in 2026.
- Business Quant data shows EPRX's Operating Expenses at $16.0 million in Q1 2026, $16.2 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 15.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.96 Mn |
| Dec 31, 2025 | 16.16 Mn |
| Sep 30, 2025 | 6.88 Mn |
| Jun 30, 2025 | 8.26 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 7.48 Mn |
| Sep 30, 2024 | 6.27 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.69 Mn |
| Dec 31, 2023 | 11.98 Mn |
| Sep 30, 2023 | 6.62 Mn |
| Jun 30, 2023 | 5.71 Mn |
| Mar 31, 2023 | 3.54 Mn |